Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-13

Study Completion Date

2025-11-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers

NCT03199690

HIV-1-infection Tuberculosis

UNKNOWN PHASE1

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

NCT02227238

HIV Infections

COMPLETED PHASE3

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

NCT01138202

HIV Infections Tuberculosis

COMPLETED PHASE2

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052

Infection, Human Immunodeficiency Virus HIV Infections

ACTIVE_NOT_RECRUITING PHASE3

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

NCT02373930

Infection, Human Immunodeficiency Virus

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label, single arm, phase II, multicenter PK study to investigate the effect of daily RPT 1200 mg on DTG exposure in participants with HIV-associated TB. Adults with HIV with newly diagnosed DS-TB who are not currently on ART will be recruited around the time of DS TB diagnosis. At study entry, the 2HPZM/2HPM regimen will be initiated for anti-tuberculosis (anti-TB) therapy and continued for 17 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-associated Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults with HIV and newly diagnosed DS-TB not currently on ART

Participants will receive daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide for 8 weeks followed by daily rifapentine-moxifloxacin plus isoniazid for 9 weeks (referred to as 2HPZM/2HPM) for anti-tuberculosis (anti-TB) therapy at study entry.

DTG-based ART at 50 mg twice daily (BID) will be started after 6 weeks of TB therapy and will be continued for 2 weeks after completion of TB therapy.

Two weeks after completion of TB therapy DTG will be reduced to standard dose 50 mg once daily (QD).

Group Type EXPERIMENTAL

Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC

Intervention Type DRUG

Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.

DTG 50 mg orally QD plus TDF/3TC

Intervention Type DRUG

DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).

2HPZM

Intervention Type DRUG

Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen

2HPM

Intervention Type DRUG

Daily rifapentine-moxifloxacin plus isoniazid regimen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC

Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.

Intervention Type DRUG

DTG 50 mg orally QD plus TDF/3TC

DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).

Intervention Type DRUG

2HPZM

Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen

Intervention Type DRUG

2HPM

Daily rifapentine-moxifloxacin plus isoniazid regimen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals ≥18 years of age at study entry.
2. Weight ≥40 kg.
3. Body mass index (BMI) \>18.5 kg/m2.
4. Ability and willingness of participant or legal guardian/representative to provide informed consent.
5. Documentation of HIV-1 status.
6. CD4+ cell count ≥100 cells/mm3 obtained within 30 days prior to study entry at any network-approved non-US laboratory that is IQA certified.
7. ART-naïve or not on ART for 12 consecutive weeks prior to TB diagnosis.
8. Willingness and eligibility to start DTG-based ART at 6 weeks, with a window of ±1 week, after starting TB treatment, with no intention to change ART for the duration of the study.
9. Documentation of pulmonary TB.
10. Willingness to start 2HPZM/2HPM therapy for DS-TB.
11. The following laboratory values obtained within 30 days prior to study entry:

* Absolute neutrophil count (ANC) \>750 cells/mm3
* Hemoglobin ≥7.4 g/dL
* Platelet count ≥50,000/mm3
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \<2.5 X the upper limit of normal (ULN)
* Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) \<2.5 x ULN
* Total bilirubin ≤1.5 x ULN
* Creatinine \<1.3 x ULN
12. For participants who can become pregnant, negative serum or urine pregnancy test at screening within 30 days prior to entry and within 48 hours prior to entry.
13. Participants who can become pregnant must agree not to participate in the conception process and if participating in sexual activity that could lead to pregnancy, must agree to use one reliable nonhormonal method of contraception.
14. Documentation of Karnofsky performance score ≥50 within 30 days prior to entry.

Exclusion Criteria

1. Breastfeeding, pregnant, or plans to become pregnant.
2. Known allergy/sensitivity or any hypersensitivity to components of the study drugs, or their formulations.
3. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
4. Requirement for ongoing use of drugs that are known to have significant drug-drug interactions with DTG or RPT.
5. Known history of acute intermittent porphyria.
6. Previous treatment for active TB disease.
7. More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
8. At the time of study entry, documentation of an M. tuberculosis isolate from the current or previous treatment episode known to be resistant to RIF or INH.
9. Known history of prolonged QT syndrome.
10. Known cirrhosis, a history of decompensated liver disease (ascites, hepatic encephalopathy, or esophageal varices).
11. Documentation of severe opportunistic infections, in the opinion of the site investigator, within 3 months of study entry.
12. Documentation of severe extra-pulmonary TB (e.g., meningitis, osteomyelitis, disseminated TB) at the time of screening.
13. Acute gout at the time of screening.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No